



**ANNUAL MEETING OF NATIONAL NTD
PROGRAMME MANAGERS IN THE WHO
AFRICA REGION**

**November 29 to
December 1, 2023**

BRAZZAVILLE, CONGO
WHO AFRICA REGIONAL OFFICE



**World Health
Organization**

African Region



**HEALTH
FOR ALL**

Session 9: Supply Chain Management

Moderator - Dr Afework Tekle

Supply Chain Management Challenges - Dr Afework Tekle, Dr Anh Tuan Le , Tunde Oladimeji, Dr DIOP, Boubacar

NTDs Supply Chain Management in Rwanda - Ladislas NSHIMIYIMANA

Optimizing last Mile NTD Medicine Supply Chain

Management in Kenya - Wyckliff Omondi

NTD Health Product Management Programme: Supply Chain Management Challenges



ANNUAL MEETING OF NATIONAL NTD PROGRAMME MANAGERS IN THE WHO AFRICA REGION

“Stepping up County Ownership to Accelerate Programmatic Action”

29 November -1 December 2023

Dr Afework Tekle, Unit Head,
Dr Anh Tuan Le, Strategic
Operations Unit
Global NTD Programme,
WHO/HQ



**World Health
Organization**



Mr DIOP, Boubacar & Mr Tunde
OLADIMEJI
WHO/AFRO/ESPEN

Outline

Management of NTD Health Products in the Road map

Program Goals and Scope

Achievements

Supply Chain Management Challenges

Available Resources

Way forward- action points

Gap assessment for each NTD



		Eradication	Elimination (interruption of transmission)	Elimination as a public health problem										Control											
		<i>Dracunculiasis</i>	<i>Yaws</i>	<i>Human African trypanosomiasis (gambiense)</i>	<i>Leprosy</i>	<i>Onchocerciasis</i>	<i>Chagas disease</i>	<i>Human African trypanosomiasis (rhodesiense)</i>	<i>Leishmaniasis (visceral)</i>	<i>Lymphatic filariasis</i>	<i>Rabies</i>	<i>Schistosomiasis</i>	<i>Soil-transmitted helminthiases</i>	<i>Trachoma</i>	<i>Buruli ulcer</i>	<i>Chikungunya</i>	<i>Dengue</i>	<i>Echinococcosis</i>	<i>Foodborne trematodiasis</i>	<i>Leishmaniasis (cutaneous)</i>	<i>Mycetoma</i>	<i>Chromoblastomycosis and other deep mycoses</i>	<i>Scabies and other ectoparasitoses</i>	<i>Snakebite envenoming</i>	<i>Taeniasis / cysticercosis</i>
Technical progress	Scientific understanding	Yellow	Green	Orange	Red	Orange	Yellow	Orange	Yellow	Green	Orange	Yellow	Yellow	Yellow	Red	Yellow	Yellow	Yellow	Yellow	Orange	Orange	Orange	Yellow	Yellow	Yellow
	Diagnostics	Yellow	Green	Orange	Red	Orange	Orange	Orange	Orange	Orange	Orange	Orange	Orange	Yellow	Red	Orange	Yellow	Red	Orange	Orange	Red	Orange	Orange	Green	Red
	Effective interventions	Green	Yellow	Yellow	Orange	Orange	Orange	Orange	Orange	Yellow	Green	Orange	Orange	Yellow	Green	Red	Orange	Green	Orange	Orange	Red	Orange	Yellow	Red	Orange
Strategy and service delivery	Operational and normative guidance	Yellow	Yellow	Orange	Orange	Orange	Orange	Orange	Orange	Green	Yellow	Orange	Orange	Yellow	Yellow	Yellow	Yellow	Yellow	Red	Green	Orange	Red	Red	Orange	Yellow
	Planning, governance and programme management	Orange	Yellow	Orange	Orange	Orange	Orange	Orange	Orange	Orange	Orange	Orange	Orange	Yellow	Orange	Orange	Red	Red	Red	Orange	Red	Red	Orange	Green	Red
	Monitoring and evaluation	Yellow	Red	Orange	Orange	Orange	Orange	Orange	Orange	Orange	Red	Orange	Yellow	Yellow	Red	Orange	Orange	Red	Red	Red	Red	Red	Red	Red	Red
	Access and logistics	Yellow	Yellow	Yellow	Orange	Orange	Orange	Green	Yellow	Orange	Red	Orange	Yellow	Green	Yellow	Yellow	Yellow	Red	Red	Red	Red	Red	Red	Red	Red
	Health care infrastructure and workforce	Yellow	Yellow	Orange	Orange	Orange	Orange	Red	Orange	Orange	Orange	Orange	Yellow	Yellow	Yellow	Orange	Yellow	Yellow	Red	Orange	Orange	Orange	Yellow	Orange	Orange
Enablers	Advocacy and funding	Orange	Red	Orange	Orange	Orange	Orange	Red	Red	Red	Orange	Orange	Red	Orange	Red	Orange	Red	Red	Red	Red	Red	Red	Red	Yellow	Red
	Collaboration and multisectoral action	Yellow	Orange	Yellow	Orange	Orange	Orange	Orange	Orange	Orange	Orange	Green	Yellow	Orange	Orange	Orange	Orange	Orange	Orange	Orange	Red	Orange	Yellow	Green	Orange
	Capacity- and awareness-building	Green	Yellow	Yellow	Orange	Orange	Orange	Orange	Orange	Orange	Red	Red	Yellow	Yellow	Red	Yellow	Green	Orange	Red	Orange	Orange	Red	Orange	Orange	Orange

Our goal is

- To improve access to quality assured NTD medicine and Health Products to all countries...to achieve the NTD Roadmap goals
 - requiring NTD interventions apply for donated or procured NTD Health Products
 - receive donated or procured NTD Health Products on time
 - Distribute/utilize the donated or procured NTD Health Products as planned and rationally
 - report on implemented activities within a defined timeframe.
 - Ensure the pharmaceutical donors and Global NTD community get those reports
- To support pooled procurement or advice countries on procuring quality assured NTD Health Products or promoting PQ
- Providing PQ to manufacturers


How?



- **Coordination of NTD Health Product donation** pharma donors, forwarders, countries and implementing partners
- **Strengthening country support activities** through closer collaboration with WHO Regional Offices and Country Offices
- **Produce guidance and capacity building tools** to NTD programmes
- Supporting the JAP Review and supply chain management process
- Expand access to NTD Health products to all NTDs through donation or negotiated price and pooled procurement
- Problem-solving country visits
- Coordinated follow-up on implementation

Joint PC process at global level

8-10 months



Joint Application Package (JAP) for PC

- Joint Request for Selected PC Medicines
- Joint Reporting Form
- PC Epidemiological Data Reporting Form

National programme

MDP
IVM

ORDER through JAP

SHIPMENT

PC Joint Application Package

A joint mechanism and a set of forms have been developed to facilitate the process of application, review and reporting as well as to improve coordination and integration among different programmes for elimination and control of lymphatic filariasis (LF), onchocerciasis (ONCHO), schistosomiasis (SCH) and soil-transmitted helminthiases (STH).

In June 2022, WHO/NTD released a fourth version of JAP.



World Health Organization

Annual Work Plan

As part of the global efforts to accelerate expansion of preventive chemotherapy (PC) for elimination and control of lymphatic filariasis, schistosomiasis, soil-transmitted helminthiases and onchocerciasis, the World Health Organization (WHO) facilitates the supply of necessary medicines. In order to request for medicines, submission of the Annual Work Plan together with the PC Epidemiological Data Reporting Form (PC EPIRF) is required.

Annual Work Plan on the key activities, technical resources, programmes, and

PC Epidemiological Data Reporting Form v.4.0

The purpose of this template PC Epidemiological Data Reporting Form (PC EPIRF) - available as an Excel file - is to provide national health authorities and data managers with a standardized tool to address these reporting challenges, facilitate integration and thereby further contribute to improving overall programme management. This template aims to standardize national reporting of epidemiological data on diseases targeted for preventive chemotherapy, improve availability and coordination of preventive chemotherapy data across the World Health Organization regions.

World Health Organization

Joint request for selected PC medicines v.4.1

As part of global efforts to accelerate expansion of preventive chemotherapy (PC) for control and elimination of lymphatic filariasis, schistosomiasis and soil-transmitted helminthiases, the World Health Organization (WHO) facilitates programmes and national schistosomiasis control programmes (NSCPs) and national onchocerciasis control programmes (NOCPs) to national schistosomiasis control programmes (NSCPs) and national onchocerciasis control programmes (NOCPs). This Excel-based tool is required to reach the target population for PC medicines.

World Health Organization

PC Joint Reporting Form v.4.2


The purpose of this template Joint Reporting Form (JRF) - available as an Excel file - is to provide national health authorities and data managers with a standardized tool to address these reporting challenges, facilitate integration and thereby further contribute to improving overall programme management. This template aims to standardize national reporting of programme implementation outcomes, improve availability and coordination of preventive chemotherapy data across the World Health Organization regions.

National authorities are requested to complete this form for submission to the World Health Organization **within 3 months** after the last round was implemented and **no later than 31 March** of the next implementation year


Structure of the application (worksheets):

INTRO	This worksheet includes guides on how to complete the joint reporting form and information about status of PC for endemic diseases in the country
COUNTRY_INFO	This worksheet includes information about administrative structure of the country, population by age group, status of endemicity for each disease, population requiring PC, planned interventions and interventions implemented
MDA1, MDA2, MDA3, MDA4, MDA5, T1, T2 and T3	These worksheets include information about endemic districts targeted for treatment with specified PC medicines, treatment plan, and number of people who received treatment by age group. Depending on co-endemicity of the diseases in a country the tool will generate respective worksheets to fill in.
DISTRICT	This worksheet includes summary of people treated by disease at the level of implementation. If data by gender is available, it requires to enter.
SUMMARY	This worksheet includes summary of people treated by disease and by PC intervention. Before


IDM Medicine Donation Management Process



CM Medicine Procurement Management Process



Diagnostics Procurement Management Process



Work with more than 12 Pharmaceutical Donors and partners on NTD Health Products




Mundo Sano



NTDs	Manufacturer	Product Name	MOU Period	Donation Commitments
Chagas disease	Bayer AG (Germany)	Nifurtimox (120 mg tablets)	2007–2025	<ul style="list-style-type: none"> Up to a total of 12,500,000 tablets for the treatment of Chagas disease
	Chemo Group (Mundo Sano)	Benznidazole (100 mg tablet; 12.5 mg tablet)	2020–2023	<ul style="list-style-type: none"> 3,000 tablets (12.5mg)/105,000 tablets (100mg)
Cystic echinococcosis	GlaxoSmithKline (GSK) (UK)	Albendazole (400mg tablets)	2022–2025	<ul style="list-style-type: none"> Up to 5 million as long as it is within the limit of the overall donation of ALB from GSK
Foodborne trematode infections (clonorchiasis and opisthorchiasis)	Bayer AG (Germany)	Praziquantel (600 mg tablets)	2020–2024	<ul style="list-style-type: none"> Within the limits of the donation of praziquantel for taeniasis/cysticercosis
Human African trypanosomiasis (HAT)	Bayer AG (Germany)	Nifurtimox (120 mg tablets)	2009–2026	<ul style="list-style-type: none"> Up to 150,000 tablets for five years, adjustable to needs to treat human African trypanosomiasis
		Suramin (1 g in vial)	2002–2026	<ul style="list-style-type: none"> Up to 10,000 vials for five years, adjustable to needs to treat human African trypanosomiasis
	Sanofi (France)	<ul style="list-style-type: none"> Eflornithine (200 mg per mL in 100 mL bottle); Melarsoprol (3.6% in 5 mL ampoule solution (180 mg of active compound); Pentamidine (200 mg powder for injection) 	2001–2026	<ul style="list-style-type: none"> Unlimited quantity for the treatment of human African trypanosomiasis
		<ul style="list-style-type: none"> Fexinidazole (600 mg tablets) 	2019–2026	
Visceral leishmaniasis (VL)	Gilead Sciences, Inc. (USA)	Liposomal Amphotericin B (lyophilized 50 mg formulation in vials) (AmBisome®)	2012–2016	<ul style="list-style-type: none"> Up to 445,000 vials for the treatment of visceral leishmaniasis in South-East Asia and East Africa
			2016–2021	<ul style="list-style-type: none"> Up to 380,400 vials for the treatment of visceral leishmaniasis in South-East Asia and East Africa
			2023-2025	<ul style="list-style-type: none"> Up to 304,700 vials for the treatment of visceral leishmaniasis in South-East Asia and East Africa
Yaws	EMS SA Pharma (Brazil)	Azithromycin (500 mg tablets)	2019–2023	<ul style="list-style-type: none"> 153 million tablets to support the global eradication of yaws.
Leprosy	Novartis (Switzerland)	<ul style="list-style-type: none"> Clofazimine MDT Adult and Children 	2000–2025	<ul style="list-style-type: none"> Up to 1,650,000 capsules for the treatment of severe erythema nodosum leprosum reactions Up to 2,478,000 blisters annually for the treatment of leprosy and its complications
	Bayer AG	Niclosamide		<ul style="list-style-type: none"> Up to a total of 2,800,000 tablets for the treatment of taeniasis

NTDs	Manufacturer	Product Name	MOU Period	Donation Commitments
Foodborne trematode infections (fascioliasis and paragonimiasis)	Novartis (Switzerland)	Triclabendazole (250mg tablets)	2016–2025	Up to 600,000 tablets for the treatment of fascioliasis and paragonimiasis
Lymphatic filariasis (LF)	Eisai (Japan)	Diethylcarbamazine citrate (100 mg tablets)	2014 until elimination of LF (current MOU runs till 2021)	<ul style="list-style-type: none"> Up to 2.2 billion tablets committed for first 7-year period for use in the preventive chemotherapy of lymphatic filariasis Extended in 2017 until elimination is achieved Amendment 1 signed for donation till end 2021
	GlaxoSmithKline (GSK) (UK)	Albendazole (400mg tablets)	Since 1997 until elimination of LF	Up to 600 million tablets annually for use in the preventive chemotherapy of lymphatic filariasis
Schistosomiasis (SCH)	Merck KGaA (Germany)	Praziquantel (600 mg tablets)	Since 2007 for an unlimited period	<ul style="list-style-type: none"> Up to 200 million tablets annually for the treatment of schistosomiasis in school-age children (notably in Africa) Since 2017, donation scaled up to 250 million tablets annually for the treatment of schistosomiasis
Soil-transmitted helminthiasis (STH)	GlaxoSmithKline (GSK) (UK)	Albendazole (400mg tablets)	2012–2025	Donation expanded by 200 million tablets annually for use in the preventive chemotherapy of soil-transmitted
	Johnson & Johnson (USA)	Mebendazole (500 mg tablets)	Until 2025	Up to 200 million tablets annually for the treatment of soil-transmitted helminthiasis in school-age children


Number of individuals received Preventive Chemotherapy (PC) interventions for at least one disease, 2010-2022 (as of 25 October 2023)



These interventions have been delivered to individuals living in areas which require PC and also in areas which may not require PC

Total number of NTD medicines supplied through WHO coordination between 2011–2022

A total of 15.6 Billion NTD Medicines in a decade




Compared to 2019- Pre-COVID situation. Reduction by:

Total number of IDM NTD medicines supplied through WHO coordination between 2011–2023



A total of 63.2 Million NTD Medicines in a decade




21


Current NTD Program Implementation and Supply Chain Management Challenges post COVID

30

Challenges: *first mile*



Challenges: last mile



Major Challenges POST COVID

- Reduced demand for medicines
- Increasing uncertainty of forecasting demands due to lack of accurate data
- Delayed provision of hard demand
- HR and funding shortage at WHO level for NTD Health Product donation management


• Major Contributing factors

- Missed or postponed MDA campaigns due to COVID pandemic
- Retrieval of unutilized stock balances at country level
- Significant local procurements by some countries who normally receive donations.
- Reduction of major funding for MDA implementation
- Lack of inventory management at sub national level- LMIS
- Lack of information on funding availability for planned MDA
- Late submission and slow regional clearance of the JAP due to unaccounted balance and low responsiveness of NTDPs
- Lack of clarity of Schisto sub district data analysis
- very slow response from recipient countries WCO (for Report/request; for shipping GL, for additional tax, etc).
- Imposition of Tax and additional payments requests


Available resources for Capacity-building

- SOP Manual, Mobile application and online training course for Supply Chain Management of NTD Health Products


SOP Manual



Mobile App



Online Course



The screenshot shows the interface of an online course titled "Supply chain management of NTD health products for NTD programmes". The course is hosted on OpenWHO. The interface includes a navigation bar with options like "Learnings", "Discussions", "Progress", "Certificates", "Collab Space", "Course Details", and "Documents". Below the navigation bar, there is a main content area with a photograph of a person wearing gloves and writing on a form, with several packets of AOTEM (Aotem) medicine and a bowl of pills nearby. The course information section on the right indicates that the course is self-paced, in English, and not disease-specific. There are buttons for "Enter course" and "Un-enroll".

Standard operating procedures
for supply chain management of health
products for **neglected tropical diseases**
amenable to preventive chemotherapy




- Released in July 2022 the standard operating procedures on supply chain management for NTDs for 11 key supply chain challenges, prepared in collaboration with the SCM Forum.
- English version:
<https://www.who.int/publications/i/item/9789240049581>
- **Translation status:**
 - Arabic , French & Spanish- translation review completed and formatting and publication soon.
 - Portuguese translation (**Estacio de Sa University, Brazil**) Translated and Under proof reading

Thanks to the following volunteers who made the translation and its review review:

- Arabic EMRO specifically **Dr Mona Osman**
- Spanish- **Mr. Moumine Yaro** from TFGH and his other **two francophone colleagues**
- Spanish PAHO specifically **Dr Ana Luciañez**
- **Portuguese: Estacio de Sa University, Brazil !.**

Mobile application on NTDs Supply Chain SOPs



- Will contain all SOPs
 - All together and
 - Individual SOPs for download
- **OpenWHO Training materials** also available through the app
- If one needs **certificate of achievement** it is inked to OpenWHO training site for registration and taking the training
- Finalized and now publicly available at:
- Android phones users :
<https://play.google.com/store/apps/details?id=org.who.NTDSUPPLY SOP>
- iPhone users
<https://apps.apple.com/us/app/ntds-supply-chain-sops-app/id6443441796>

- An online training course on supply chain management of NTD health products available in the NTD Channel in the OpenWHO platform.

<https://openwho.org/courses/NTDs-supply-chain-managemen>

Supply chain management of NTD health products for NTD programmes OpenWHO

Course Administration ▾

Course is available

Learnings

Discussions

Progress

Certificates

Collab Space

Course Details

Documents

Announcements



Share

Tweet

Share

Mail

A key component of achieving control and elimination of neglected tropical diseases (NTDs) is effective supply chain management of preventive chemotherapy drugs for Mass Drug Administration (MDA) for trachoma, river blindness, lymphatic filariasis, soil-transmitted helminthiasis and schistosomiasis. This course explains the end-to-end process from planning and submitting donated drug requests through to waste management of expired and unserviceable stock and reverse logistics of unused tablets. It is essential knowledge for all levels of the health system that must work together to implement MDA.

Photo: WHO/ Y. Shimizu

Self-paced

Language: English

Not disease specific

Enter course

Un-enroll

Course Dashboard

Enrollments

4,809 Total (4,723 non-deleted)

+3 Last 24 hours

8 At start (8 non-deleted)


Activity

3,419 Current Shows
71% ratio based on total enrollments

Certificates


923 Records of Achievement
0% ratio based on shows at middle

NO-SHOWS







Forum and Helpdesk

- POSTS
- TOPICS
- POSTS IN COLLAB SPACES
- TOPICS IN COLLAB SPACES
- HELPDESK TICKETS



- Posts
- Topics
- Posts in collab spaces
- Topics in collab spaces
- Helpdesk tickets



Translation of the course to French & Arabic is ongoing

Frequently Asked Question on Joint Application Package (JAP)- FAQ on JAP

Frequently asked questions on the joint application package for preventive chemotherapy

Planning, requesting medicines and reporting

[Frequently asked questions on the joint application package for preventive chemotherapy. Planning, requesting medicines and reporting \(who.int\)](https://www.who.int/teams/control-of-neglected-tropical-diseases/interventions/strategies/preventive-chemotherapy/joint-application-package)



<https://www.who.int/teams/control-of-neglected-tropical-diseases/interventions/strategies/preventive-chemotherapy/joint-application-package>

- JAP Working Group
- Will contain all FAQ and web core FAQ
 - General
 - JRSM
 - JRF & EPRF
 - APW
- Final FAQ is published in WHO web page
- Translation to Arabic, French, Portuguese and Spanish has been done.

NTDeliver:




<https://www.ntdeliver.com/>

- Tracking, Planning and forecasting and reporting

- Easily accessible

NTDeliver: Overview



Login

Email

teklea@who.int

Password

.....

Sign In

[Forgot your password?](#)

Country Summary

- Select a Country -

Public Dashboards

- Select Public Dashboard -

Actions Points:

- Countries are responsible and accountable to the NTD medicine donation and needs to give priority during MDA implementation and timely reporting.
- Account all remaining balances in some countries. Respond to WHO promptly.
- Provide Green Light on time and facilitate tax exemption and clearance at the port.
- Strengthen or develop a **Logistic Management Information system (LMIS)** for NTD Health product to improve last mile Supply chain management and integrate in existing system.
- Provide realistic short-term forecasts of medicines to be used by countries.
- Monitor funding available at implementation unit level.
- Produce a database where realistic funding available for implementation next two years.
- Rollout a monitoring and evaluation framework for donated medicines to ³¹



谢谢, gracias, شكراً, merci, kiitos, Спасибо, አመሰግናለሁ, obrigado, thank you

Session 8: Supply Chain Management

Moderator - Dr Afework

NTDs Supply Chain Management in Rwanda - Ladislav NSHIMIYIMANA



World Health
Organization



NTDs Supply Chain Management in Rwanda

Ladislav NSHIMIYIMANA, MPH, MAPPM
NTDs and Other Parasitic Diseases Unit
Rwanda Biomedical Centre



Challenges of Rwanda NTD Supply Chain before making changes



- The NTD program did not have the inventory of all donated medicines to compare with treatment reports
- Medicines distribution from districts to health centers used to be done out of the e-LMIS making impossible their traceability from districts to Community was impossible
- NTD program had a vertical supply chain, taking drugs to hospitals and hospital to HCs without using eLMIS (used in normal supply chain passing through district pharmacies)
- MDA medicines were stored in staff's offices not in pharmacy stock as for other medicines
- There was not reporting of drug balance, only the reported coverage
- MDA Data were reported in excel with the room of manipulation at different level



Monitoring the use of donated medicines every year —received, distributed & balance



COUNTRIES	Year	# ALB tablets donated via WHO	# MBD tablets donated via WHO	# Tablets distributed as per official report	BALANCE of tablet donated via WHO by selected year	EXPLANATIONS
Rwanda	2012	5,200,000		2,654,947	2,545,053	
Rwanda	2013			2,892,865		As Albendazole were few, Mebendazole (347,812) was used to d
Rwanda	2014	5,900,000		3,026,426	2,873,574	The treated children are not 3,323,164 but 3,026,426 in the FINA
Rwanda	2015	6,355,000	1,302,000	6,753,573	3,777,001	The treated Pre-SAC with donated Mebs were not considered th SAC) 6,753,573 (Round 1: 2,922,992 SAC, Round 2:2,689,649 SAC
Rwanda	2016	3,512,000		3,323,164	3,965,837	Treated No. is OK
		Gov't contribution in drugs: 1,000,000 tabs				The quantity is used in deworming of some at-risk groups (lactati cover some gaps
Rwanda	2017	6,625,000		6,796,282	3,794,555	The treated children are 6,796,282 and not 7,752,383. It seems a
Rwanda	2018	2,657,000		7,144,162	- 692,607	The quantity of 1 million tablets purchased by the Government i
Rwanda	2019	7,225,000		7,387,724	- 162,724	provided by World Vision International are used to cover this ga
Rwanda	2020	7,232,000		3,810,378	3,421,622	Treated SAC: 3,369,257 & adults: 441,121 in June 2020
Rwanda	2021	7,532,000	17,896,000	27,061,325	1,788,297	EXPLANATIONS ON USE/ POTENTIAL USE: Round 1 (Feb-March 21): considered as roun due to COVID-19; Round 2 (June 2021) considered as round 1 in 2021: the reporting i target was 11,857,278 (1,504,424 PRE-SAC + 3,450,974 SAC + 6,902,880 ADULTS). Bec
	2022	-	25,032,297	21,170,045	5,650,549	Following the campaign MDA in May (Pre-SAC 1,460,132 treated), July (8,760,988 SAC (10,948,925 all age groups treated), the theoretical balance by December 24, 2022 is

ALB&Mebs


PZQ_WHO_Merck

Graphs on quantities received

Facing challenges of where to get quantities of drugs donated in last years?,
please visit <https://www.ntdeliver.com/>




Integrated NTDs Program Supply Chain and M&E





What did we change for SCM? use of eLMIS when Ordering and reporting & use of stock cards





Best practices

- Monitoring the use of donated medicines improves accountability and transparency
- The vertical supply chain was discouraged to integrated in routine supply chain
- Through instructions:
 - the e-LMIS was made a standard tool for ordering and reporting MDA drugs
 - The vertical supply chain system was replaced by integrated suppliant chain down to village/school
 - MDA medicines were since then stored in pharmacy stock as for other medicines, each drug with specific stock card
 - Remaining drugs was encouraged to be reported in e-LMIS whereas reported coverage hasb been always reported in HMIS
 - MDA data were at the first time reported in HMIS (DH2), since 2021.



Thank you

Murakoze

ladislas.nshimiyimana@rbc.gov.rw

Optimizing last Mile NTD Medicine Supply Chain Management in Kenya


Wyckliff Omondi

Head, Vector Borne & Neglected Tropical Diseases Unit-MoH


01st December 2023



Ministry of Health



Overview of NTDs in Kenya



Control
Chikungunya
Dengue
Rabies
Snake bite
envenoming
Leishmaniasis
Scabies

Elimination by 2030
Schistosomiasis
Soil Transmitted
Helminths
Taeniasis/Cysticercosis
Trachoma

Dossier submission
Human African
Trypanosomiasis
Onchocerciasis by
2027
Lymphatic filariasis by
2025

Status unknown
Yaws
Buruli Ulcers

Eliminated

Guinea worm

NTD pharmaceutical partners



ministry of Health

Product	Disease	Donor /Manufacturer	Coordination
Diethylcarbamazine (DEC) tabs 100mg	LF	Eisai	WHO
Albendazole tabs 400mg	LF & STH	GlaxoSmithKline	WHO
Mebendazole tabs 500mg	STH	Johnson & Johnson	WHO
Ivermectin (Mectizan®) tabs 3mg	LF & Oncho	Merck & Co. [MSD]	MDP
Praziquantel tabs 600mg	SCH	Merck Serono	WHO
Zithromax® tabs 250mg	Trachoma	Pfizer	ITI
Zithromax® POS 1200mg/30ml	Trachoma	Pfizer	ITI
Amphotericin B liposome for inj. (AmBisome®)	VL	Gilead	WHO



Challenges In supply chain



- Customs duties waiver delays at port of entry
- Irregular and incomplete Inventory management & reporting to the NTD programs
- Weak coordination on supply chain management between MoH and Partners
- Weak coordination between national and peripheral levels
- Lack of digital platform to enhance visibility at subnational levels



Challenges in Supply chain



ministry of Health

- **Divergent global and country priorities and strategies**

Global donation plans are standardized or designed with a broader perspective and divert from Country specific plans

- **Sub optimal storage conditions at the peripheral health facilities**

Variation in storage conditions in various peripheral facilities levels may compromise prolonged storage of NTDs commodities




Lessons learnt-solutions



ministry of Health

- Review of MDA training manual to include supply chain management during MDA
- Development of supply chain management plan
- Increased visibility and accountability; PZQ supply chain
- Periodic checks in the central stores (FIFO)
- Mainstreaming NTDs products into national health systems such as eLMIS, eCHIS
- Training on WHO requisition forms





Thankyou for your attention!